# Debate Matchup Judgment Report

**Claude Fable 5.1 (high)** vs **Grok 4.6 (high)**

- Paired result: **Tie**
- Mean entertainment: `7.83 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Health insurers should be required to cover FDA-authorized anti-obesity medications when clinically indicated, with value-based pricing or outcomes-based contracts to control spending.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0632__claude-fable-5-1-high__grok-4.6-high__s0__tpl_placement_active_20260813a.md): PRO = **Claude Fable 5.1 (high)**, CON = **Grok 4.6 (high)**
- [Debate B transcript](../../../transcripts/prop_0632__grok-4.6-high__claude-fable-5-1-high__s1__tpl_placement_active_20260813a.md): PRO = **Grok 4.6 (high)**, CON = **Claude Fable 5.1 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0632__claude-fable-5-1-high__grok-4.6-high__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Claude Fable 5.1 (high)**, CON = **Grok 4.6 (high)**
- Judged result: Split `2-1` for **Grok 4.6 (high)**.
- Entertainment scores: `8`, `7`, `8`
- Mean signed raw margin (PRO+): `-0.30`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.6 Sol (high) | A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON) | Grok 4.6 (high) | -1.3 | -1.23 | 8.0 |
| Muse Spark 1.1 (high) | A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON) | Grok 4.6 (high) | -1.6 | -1.70 | 7.0 |
| Qwen 3.7 Max | A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON) | Claude Fable 5.1 (high) | +2.0 | +1.70 | 8.0 |

### Judge Notes

- **GPT-5.6 Sol (high)** (A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON)): Side B won a competitive debate by showing that successful treatment and brand competition do not establish that outcomes contracts can control aggregate spending for a large, continuously treated population. Side A compellingly framed exclusion as inequitable, but its answer ultimately assumed centralized price-setting and enforceable terms beyond what the proposition specified. The two clipped turns were an additional execution cost.
  Most decisive rebuttal noted: Side B’s response to A4.1-A4.2 was decisive: dropping one brand preserves some leverage, but it does not restore the ability to reject the costly indication if every manufacturer demands a high price. A’s fallback to negotiator-imposed terms added a mechanism not clearly contained in the motion.
- **Muse Spark 1.1 (high)** (A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON)): CON wins the decisive leverage/cost-control clash. PRO redefined mandate as "cover class on value terms" and brand-level exclusion as the hard no, but B's pressure questions exposed that if every maker prices "value" near list, coverage still bites and the indication-level walk-away dies. B showed outcomes refunds don't restore premiums already paid for lifelong mass therapy with high churn and job changes, unlike finite hep C/gene therapies. A suffered execution costs from two clipped turns and never named a case where fragmented refusals beat pooled negotiation. Scale as insurance-design principle survived PRO's diabetes analogy.
  Most decisive rebuttal noted: B4 A1/A2 + B2 leverage reply — showing brand-swapping under a required obesity indication is not a hard no and outcomes language pays first, recaptures later, leaving non-users funding the benefit.
- **Qwen 3.7 Max** (A = Claude Fable 5.1 (high) (PRO); B = Grok 4.6 (high) (CON)): Side A wins by decisively reframing the core clash over market leverage. While Side B argued that a coverage mandate destroys the insurer's "hard no," Side A successfully demonstrated that the current "hard no" (denying patients) fails to lower prices, whereas a mandate enables a brand-level "hard no" that forces manufacturers to compete for a guaranteed mass market. Side A also rhetorically dismantled Side B's "scale" argument, exposing it as a principle that withholds treatment precisely because a disease is common. Side A's case was more cohesive, morally compelling, and economically coherent.
  Most decisive rebuttal noted: Side A's dismantling of the "hard no" argument in Rebuttal 1 and Closing, showing that fragmented patient denials do not create manufacturer leverage, while formulary exclusion (brand-swapping) in a guaranteed market does.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0632__grok-4.6-high__claude-fable-5-1-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **Grok 4.6 (high)**, CON = **Claude Fable 5.1 (high)**
- Judged result: Split `2-1` for **Claude Fable 5.1 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `-0.83`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.6 Sol (high) | A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | Claude Fable 5.1 (high) | -1.7 | -1.61 | 8.0 |
| Muse Spark 1.1 (high) | A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | Grok 4.6 (high) | +1.2 | +1.27 | 8.0 |
| Qwen 3.7 Max | A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | Claude Fable 5.1 (high) | -2.0 | -1.70 | 8.0 |

### Judge Notes

- **GPT-5.6 Sol (high)** (A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): B won by showing that broad mandatory coverage creates large immediate costs while the measurable short-term outcomes do not establish the long-term savings needed to justify them. A answered the formulary and refund questions directly, but never proved that competition or clawbacks would control aggregate spending. B's two clipped turns reduce the margin but do not erase its stronger comparative case.
  Most decisive rebuttal noted: B's strongest exchange exposed the mismatch in A's outcomes contracts: weight and glucose are measurable but usually improve, while avoided complications are harder to attribute and may occur after patients discontinue or leave the plan. A proposed nonresponse and discontinuation refunds, but B persuasively answered that predictable refunds can be priced into successful treatments rather than generating meaningful population-level savings.
- **Muse Spark 1.1 (high)** (A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): PRO maintained a cleaner path: mandate covers the patient not the list price, with competition for preferred status and refunds for non-response/discontinuation. CON conceded in R2 that some clinically indicated patients would be denied, leaving the same plan to pay diabetes/apnea/joint complications with no refund, and never resolved the BILL-timing transfer. Despite strong CON pressure on duopoly and outcomes-shrink, PRO's walk-away distinction and direct A1/A2 answers under meta-rules outweigh two clipped CON turns.
  Most decisive rebuttal noted: A2.1-A2.3 patient-vs-price walk distinction answering B1.1-B1.2, then tested by B2.6-B2.7 exposing the outcomes contract shrinking from hard events to in-year weight; A4.1-A4.3 recovers by defining refund triggers on threshold miss and class-not-brand coverage.
- **Qwen 3.7 Max** (A = Grok 4.6 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): Side B wins by decisively exposing the internal contradiction in the proposition: a coverage mandate destroys the negotiating leverage necessary for value-based pricing to work. B effectively dismantled A's reliance on formulary switching by pointing out that "clinically indicated" exceptions allow prescribers to bypass preferred drugs, a point A ultimately conceded. Furthermore, B's rebuttal to the cost-offset argument—that the mandate merely staples a massive, immediate pharmacy bill in front of the eventual complication bill, especially given high discontinuation rates—was economically sound and rhetorically devastating. Side A relied heavily on moral framing but could not overcome B's structural and economic takedowns.
  Most decisive rebuttal noted: Side B's dismantling of the "outcomes-based contract" defense, demonstrating that measurable outcomes (weight loss) are reliable enough that sellers rarely pay refunds, while the outcomes that justify the cost (avoided cardiovascular events) are unmeasurable across churning enrollment, effectively neutralizing PRO's primary cost-control mechanism.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0632`
- Side-swap group ID: `prop_0632__claude-fable-5-1-high__grok-4.6-high__tpl_placement_active_20260813a`
- Raw paired winner: **Tie**
- Mean normalized margin for Claude Fable 5.1 (high): `+0.13`
- Complete side swap: `yes`
- Included in ratings: `yes`
